Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
Rhea-AI Summary
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, QNTM gained 41.92%, reflecting a significant positive market reaction. Argus tracked a peak move of +38.2% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $13M to the company's valuation, bringing the market cap to $45M at that time. Trading volume was exceptionally heavy at 16.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers like MNOV, ABVC, APLT, DTIL and PMVP all showed negative moves (e.g., -1.31%, -0.44%, -1.77%, -2.19%, -0.79%), while QNTM’s pre-news move of -0.19% was smaller, indicating more stock-specific dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Private placement | Neutral | -0.2% | Non-brokered private placement and ATM termination with modest negative move. |
| Dec 01 | Lawsuit media segment | Neutral | -11.7% | Final W5 segment on USD $700M lawsuit linked to double-digit decline. |
| Nov 28 | Lawsuit media segment | Neutral | -15.0% | Repeat W5 Part 2 airing on alleged manipulation with sharp negative move. |
| Nov 27 | Lawsuit media segment | Neutral | -15.0% | W5 Part 2 coverage of alleged manipulation linked to steep selloff. |
| Nov 26 | Lawsuit media launch | Neutral | +41.9% | Initial W5 three-part series announcement with strong positive price reaction. |
Recent history shows sharp volatility tied to W5 coverage of the USD $700 million lawsuit: an initial large upside reaction followed by significant negative moves on subsequent segments and later mild pressure around a private placement.
Over the last few weeks, Quantum BioPharma’s news flow centered on its USD $700 million market-manipulation lawsuit and related W5 coverage. The initial Nov 26 W5 feature coincided with a 41.92% gain, while Parts 2 and the final segment on Nov 27–28 and Dec 1 saw declines of -14.99% and -11.65%. A Dec 10 private placement and ATM termination then paired with a modest -0.19% move, underscoring ongoing legal and financing overhangs.
Market Pulse Summary
The stock surged +41.9% in the session following this news. A strong positive reaction aligns with prior trading around W5 coverage, where the initial Nov 26 segment coincided with a 41.92% gain. The news again spotlights the USD $700 million lawsuit and alleged “stock spoofing,” a theme already linked to sharp moves. However, past follow-up segments saw double-digit declines, underscoring that media-driven spikes have historically been volatile and vulnerable to reversal as attention normalizes.
Key Terms
stock spoofing financial
market manipulation financial
multiple sclerosis medical
AI-generated analysis. Not financial advice.
TORONTO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation.
Top CTV News journalist and W5 investigative reporter Jon Woodward describes Part One of the series in an article entitled, “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?” The series explores the phenomenon of “stock spoofing,” a market manipulation tactic that is illegal in both Canada and the United States, and the basis of a USD
The first of three parts of the W5 investigative series can be viewed today on CTV News at: W5: MS research derailed by stock market spoofing: lawsuit
Quantum BioPharma Chief Executive Officer Zeeshan Saeed commented, “We thank W5 for their important investigation into the illegal, but little known, practice of stock spoofing and some of its harmful effects on retail investors. Our goal has always been to bring Lucid-MS – a potentially game-changing drug that in animal studies has been shown to stop and even reverse the degradation of nerve cells (a hallmark of multiple sclerosis) giving back mobility and control to the body unlike any drug today for the benefit of millions of people around the world who courageously live with this progressive and debilitating disease. By shining a light on our experience with alleged stock market manipulation, we hope to prevent other companies, their shareholders and their beneficiaries, from experiencing what we have been through.”
For more information visit: www.quantumbiopharma.com
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
Forward-Looking Information
This press release contains certain "forward-looking statements" within the meaning of applicable securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as “believes”, “hopes”, “alleges”, “pending”, “further”, or variations of such words and phrases or statements that certain actions events or results “may”, “could”, “which”, or “will” and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements regarding: the Company’s ongoing litigation against major financial institutions; the potential outcome or judgment value; expectations regarding whistleblower submissions and related rewards; continued market integrity initiatives; future business performance and possible acquisitions.
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the ability to obtain and validate whistleblower evidence; the timing and outcome of legal proceedings; resolution of ongoing litigation on favourable terms, availability and sufficiency of litigation funding; continued regulatory compliance and market stability for the Company’s operations.
The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the adverse outcome of legal actions; the receipt and credibility of whistleblower disclosures; changes in applicable laws and regulations; the actions of third parties involved in alleged manipulation; evolving market dynamics; the sufficiency of future litigation proceeds to fund the Company’s whistleblower reward; the continued ability to obtain sufficient litigation funding; limited future growth opportunities, and reliance on key personnel.
Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com